Your browser doesn't support javascript.
loading
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Hargrove, Diane M; Alagarsamy, Sudarkodi; Croston, Glenn; Laporte, Régent; Qi, Steve; Srinivasan, Karthik; Sueiras-Diaz, Javier; Wisniewski, Kazimierz; Hartwig, Jennifer; Lu, Mark; Posch, Alexander P; Wisniewska, Halina; Schteingart, Claudio D; Rivière, Pierre J-M; Dimitriadou, Violetta.
Afiliación
  • Hargrove DM; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Alagarsamy S; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Croston G; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Laporte R; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Qi S; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Srinivasan K; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Sueiras-Diaz J; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Wisniewski K; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Hartwig J; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Lu M; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Posch AP; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Wisniewska H; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Schteingart CD; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Rivière PJ; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.).
  • Dimitriadou V; Ferring Research Institute, Inc., Ferring Pharmaceuticals, San Diego, California (D.M.H., S.A., G.C., R.L., S.Q., K.S., J.S.-D., K.W., J.H., M.L., A.P.P., H.W., C.D.S., P.J.-M.R.) and VectivBio AG, Basel, Switzerland (V.D.) violetta.dimitriadou@vectivbio.com.
J Pharmacol Exp Ther ; 373(2): 193-203, 2020 05.
Article en En | MEDLINE | ID: mdl-32075870
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Síndrome del Intestino Corto / Péptido 2 Similar al Glucagón Límite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Síndrome del Intestino Corto / Péptido 2 Similar al Glucagón Límite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Año: 2020 Tipo del documento: Article